Annexuzlimab

Synonyms: MDX-124
Annexuzlimab 是一种人源化 IgG1 单克隆抗体,可特异性结合 ANXA1,干扰其与甲酰肽受体 1 和 2 (FPR1/2) 的相互作用,靶向分泌的 ANXA1 以阻止 FPR1/2 激活,从而阻滞细胞周期进程、导致癌细胞在 G1 期累积并减少癌症进展,可用于三阴性乳腺癌、胰腺癌和骨肉瘤的研究。
Annexuzlimab
产品编号: MS-M06633 纯度: 98.67%
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

Annexuzlimab 是一种人源化 IgG1 单克隆抗体,可特异性结合 ANXA1,干扰其与甲酰肽受体 1 和 2 (FPR1/2) 的相互作用,靶向分泌的 ANXA1 以阻止 FPR1/2 激活,从而阻滞细胞周期进程、导致癌细胞在 G1 期累积并减少癌症进展,可用于三阴性乳腺癌、胰腺癌和骨肉瘤的研究。

生物实验数据

生物活性 Annexuzlimab is a humanized IgG1 monoclonal antibody that specifically binds ANXA1 and interferes with its interaction with formyl peptide receptors 1 and 2 (FPR1/2); by targeting secreted ANXA1, it prevents FPR1/2 activation, thereby blocking cell cycle progression, causing cancer cells to accumulate in G1 phase, and reducing cancer progression, and it can be used for research on triple-negative breast cancer, pancreatic cancer, and osteosarcoma.
IC50 & Target

Annexin A1/ANXA1

体外研究
(In Vitro)

Annexuzlimab (MDX-124) (2.5-10 μM;72 h) 以剂量依赖性方式显著降低表达 ANXA1 的人类癌细胞系的增殖能力,其中 10 μM 在部分乳腺癌和卵巢癌细胞系中可导致 >50% 的活力下降,但对不表达 ANXA1 的肺癌细胞系无影响。
Annexuzlimab (10-25 μM;24 h) 可诱导剂量依赖性的 G1 期细胞周期阻滞,其中 25 μM 的作用最为显著 (MDA-MB-231 细胞 G1 期增加 33.5%,A549 细胞增加 21.2%,BxPC-3 细胞增加 10.8%),且不诱导细胞凋亡。
Annexuzlimab (5 μM;72 h) 不会诱导 MCF-7 乳腺癌细胞或 Caco-2 结直肠癌细胞发生凋亡。
Annexuzlimab 处理骨肉瘤细胞系可显著抑制细胞生长,其机制是通过剂量依赖性的细胞周期阻滞,并显著降低骨肉瘤细胞系的迁移能力。

Cell Proliferation Assay

Cell Line: MCF-7, HCC1806, MDA-MB-231, MCF-7/TAMR7, BxPC-3, MIA PaCa-2, PANC-1, A2780, A2780cis, A2780ADR, Caco-2, HCT116, SW480, NCI-H69/CPR, A549, COR-L23, COR-L23.5010
Concentration: 2.5-10 μM
Incubation Time: 72 h
Result: Caused a significant dose-dependent reduction in cellular proliferation in all ANXA1-expressing breast, pancreatic, ovarian, colorectal, and some lung cancer cell lines compared to IgG1 isotype control; At 10 μM, MCF-7, HCC1806, and MDA-MB-231 had >50% viability reduction, MCF-7/TAMR7 had 21% reduction, BxPC-3 had 40% reduction, MIA PaCa-2 had 20% reduction, PANC-1 had 34% reduction, A2780 had 31% reduction, A2780cis had 48% reduction, A2780ADR had 72% reduction, Caco-2, HCT116, and SW480 had significant reduction, NCI-H69/CPR had 36% reduction, A549 had 37% reduction; Showed no anti-proliferative activity in non-ANXA1-expressing COR-L23 and COR-L23.5010 lung cancer cells.

Cell Cycle Analysis

Cell Line: BxPC-3, MIA PaCa-2, MDA-MB-231, A549
Concentration: 10 μM, 25 μM
Incubation Time: 24 h
Result: Induced a dose-dependent G1 phase cell cycle arrest compared to untreated control cells; At 25 mM, MDA-MB-231 had a 33.5% increase in G1 phase and 29.1% decrease in S phase, A549 had a 21.2% increase in G1 phase and 18.3% decrease in S phase, BxPC-3 had a 10.8% increase in G1 phase and 10.4% decrease in S phase; Did not induce apoptosis (no sub G0/G1 peak observed).

Apoptosis Analysis

Cell Line: MCF-7, Caco-2
Concentration: 5 μM
Incubation Time: 72 h
Result: Showed no significant difference in the percentage of early or late apoptotic/necrotic cells compared to untreated control cells.
体内研究
(In Vivo)

Annexuzlimab (1 mg/kg; i.v.; 在第 1 天和第 8 天给药) 在 BALB/c 小鼠三阴性乳腺癌模型中抑制肿瘤生长 (肿瘤生长抑制率为 23%)。

Animal Model: BALB/c (female, 9 weeks old, orthotopic inoculation with 4T1-luc murine triple-negative breast cancer cells)
Dosage: 1 mg/kg
Administration: i.v.; two doses on day 1 and day 8
Result: Significantly inhibited tumour growth versus vehicle control, achieving 23% tumour growth inhibition by day 15. Observed no noticeable change in body weight throughout the study.
性状 液体
颜色 Colorless to light yellow

化学信息

别名 MDX-124

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Shipping with dry ice.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础